DUBLIN–(BUSINESS WIRE)–The “Proliferative Diabetic Retinopathy Market – Growth, Trends, COVID-19 Impact, and Forecasts (2022 – 2027)” report has been added to ResearchAndMarkets.com’s offering.
The Proliferative Diabetic Retinopathy Market is expected to register a CAGR of 9.4% during the forecast period.
Regeneron Pharmaceuticals Inc
Hoffmann-La Roche (Genentech)
Proliferative diabetic retinopathy is a complication of diabetes caused by changes in the blood vessels of the eye which can lead to other serious eye problems, which may cause long term vision loss if not treated. Proliferative diabetic retinopathy is the most advanced stage of diabetic retinopathy which is characterized by the growth of new vessels on the surface of the retina.
Some of the signs and symptoms are progressive loss of vision, fine to severe loops of new vessels that may grow on the optic disc and these new vessels may leak and resulting in retinal edema and so on. The major risk factors for proliferative diabetic retinopathy (PDR) include the duration of diabetes, for 30-34 years of diabetes increase the risk of retinopathy by 65%, according to the reports published by the Columbia University. Hence, the rising prevalence of diabetes is directly contributing to the further increase in the prevalence of proliferative diabetic retinopathy (PDR).
Key Market Trends
Anti-VEGF Agents Segment is Expected to Witness a Healthy CAGR
The recent research studies suggest that in cases of proliferative diabetic retinopathy, high levels of the vascular endothelial growth factor being detected in fibrovascular tissues of eyes of diabetic patients have prompted the use of anti-VEGF as the most effective and efficient management method. According to the International Agency for the Prevention of Blindness, by the year 2040, about 224 million (35%) people worldwide will have some form of diabetic retinopathy, in addition, 70 million (11%) people will have vision-threatening diabetic retinopathy .
Anti-VEGF agents segment holds a significant market share in the proliferative diabetic retinopathy market and is anticipated to show a similar trend over the forecast period due to effective treatment which resulted in improvements in visual acuity of patients with proliferative diabetic retinopathy when compared to improvements observed in treatment by using corticosteroids.
Rising prevalence of diabetic retinopathy and the availability of advanced technology are the key driving factors in the Anti-VEGF agent’s segment.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period
North America is expected to hold a major market share in the global proliferative diabetic retinopathy market due to rising prevalence of diabetes and diabetic retinopathy and availability of advanced technology and minimally invasive laser technique in this region. According to the Centers for Disease Control and Prevention, approximately 4.2 million adults had diabetic retinopathy and 655,000 had vision-threatening diabetic retinopathy. Furthermore, increasing healthcare expenditure and presence of well-established healthcare infrastructure is also fueling the growth of the overall regional market to a large extent.
Key topics covered:
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Prevalence of Diabetes Increases Risk of Diabetic Retinopathy
4.2.2 Availability of Advanced Technology and Minimally Invasive Laser Technique
4.3 Market Constraints
4.3.1 Extended Approval Time for Drugs
4.4 Porter’s Five Force Analysis
5 MARKET SEGMENTATION
5.1 By Treatment Type
5.1.1 Anti-VEGF Agents
5.1.3 Laser Surgery
6 COMPETITIVE LANDSCAPES
6.1 Company Profiles
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
For more information about this report visit https://www.researchandmarkets.com/r/20n647